F1The securities reported herein were acquired pursuant to the Agreement and Plan of Merger, dated as of May 3, 2016 (the "Merger Agreement"), by and among IMS Health Holdings, Inc. ("IMS") and Quintiles Transnational Holdings Inc. (the "Issuer"), whereby IMS merged with and into the Issuer with the Issuer surviving the merger (the "Merger"). At the effective time of the Merger, each share of Common Stock of IMS (the "IMS Shares"), issued and outstanding immediately prior to such time (other than IMS Shares held by IMS in treasury or owned by the Issuer or any of their direct or indirect subsidiaries) was cancelled and ceased to exist and was converted into the right to receive 0.3840 of validly issued, fully paid and non-assessable shares of Common Stock of the Issuer, par value $0.01 per share (the "Issuer Shares").
F2David Bonderman and James G. Coulter are sole shareholders of each of (i) TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors"), (ii) TPG Advisors VI, Inc. ("Advisors VI"), (iii) TPG Advisors V, Inc. ("Advisors V") and (iv) TPG Biotech Advisors, Inc. ("Biotech Advisors" and, together with Group Advisors, Advisors VI, Advisors V and Messrs. Bonderman and Coulter, the "Reporting Persons").
F3Group Advisors is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar V Advisors, LLC, (ii) TPG GenPar VI Advisors, LLC and (iii) TPG Biotechnology GenPar III Advisors, LLC. TPG GenPar V Advisors, LLC is the general partner of TPG GenPar V, L.P., which is the general partner of each of (i) TPG Partners V, L.P., which directly holds 17,755,378 Issuer Shares, (ii) TPG FOF V-A, L.P., which directly holds 46,448 Issuer Shares, and (iii) TPG FOF V-B, L.P., which directly holds 37,454 Issuer Shares.
F4TPG GenPar VI Advisors, LLC is the general partner of TPG GenPar VI, L.P., which is the general partner of TPG Partners VI, L.P., which directly holds 17,769,038 Issuer Shares. TPG Biotechnology GenPar III Advisors, LLC is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P., which directly holds 733,121 Issuer Shares. Advisors VI is the (i) general partner of TPG FOF VI SPV, L.P., which directly holds 70,241 Issuer Shares, and (ii) managing member of TPG Iceberg Co-Invest LLC, which directly holds 6,109,343 Issuer Shares.
F5Advisors V is the general partner of TPG Quintiles Holdco II, L.P., which directly holds 6,775,964 Issuer Shares. Biotech Advisors is the general partner of TPG Quintiles Holdco III, L.P. (together with TPG Partners V, L.P., TPG FOF V-A, L.P., TPG FOF V-B, L.P., TPG Partners VI, L.P., TPG Biotechnology Partners III, L.P., TPG FOF VI SPV, L.P., TPG Iceberg Co-Invest LLC and TPG Quintiles Holdco II, L.P., the "TPG Funds"), which directly holds 354,570 Issuer Shares.
F6Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and each of the TPG Funds disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or such TPG Fund's pecuniary interest therein, if any.
F7The TPG Funds have entered into a Shareholders Agreement, dated as of May 3, 2016 (as supplemented and amended, the "Shareholders Agreement"), with certain other holders (the "Holders") of Issuer Shares. Because of the relationship between the TPG Funds and the Holders as a result of the Shareholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Issuer Shares held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Issuer Shares held by the Holders.
F8Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks

(9) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (10) Clive Bode is signing on behalf of both Messrs. Bonderman and Coulter pursuant to authorization and designation letters dated June 19, 2015, which were previously filed with the Securities and Exchange Commission.